ACOG
Neutral signalScored 2026-08-27 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Alpha Cognition Inc
- Nom
- Alpha Cognition Inc
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $125.6M
- Employés
- 71
- PDG
- Michael E. McFadden
- Site web
- https://www.alphacognition.com
- Marché
- CAPNCHPGDTSQFGBIMAASNOEM
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 10000 titres (~96200 USD)
- Insiders
- Wills Robert James
- Total bought
-
$96,200
Avg buy (VWAP, 90d window) $9.62 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-21
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-21 | Wills Robert James | Buy · P | 10,000 | $9.62 | $96,200 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-27 Drivers: fundamentals. Moteurs : fondamentaux.
ACOG presents a meaningful catalyst signal with insider buying following a strong Q2 revenue beat (+71% sequential) and a European patent grant for ZUNVEYL, but the deeply deteriorated fundamentals (EBIT margin of…
The first sentence of the analysis written for ACOG on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 8.65 · operating margin -222% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 81.3% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -221.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -221.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -221.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 8.654 | 14.997 | 0.731 | 0.575 | 6.751 | |
| Quick Ratio | 8.093 | 14.813 | 0.731 | 0.575 | 6.751 | |
| Solvency Ratio | -1.198 | -1.570 | -1.910 | -2.815 | -5.052 | |
| Cash Ratio | 7.240 | 14.488 | 0.569 | 0.514 | 6.269 | |
| Price To Earnings Ratio | -5.556 | -2.916 | -1.849 | -1.589 | -0.761 | |
| Price To Earnings Growth Ratio | 0.132 | 0.062 | 0.051 | 0.033 | -0.003 | |
| Forward Price To Earnings Growth Ratio | 0.132 | 0.062 | 0.051 | 0.033 | -0.003 | |
| Price To Earnings Diluted Ratio | -5.556 | -2.916 | -1.849 | -1.589 | -0.761 | |
| Price To Earnings Diluted Growth Ratio | 0.132 | 0.062 | 0.051 | 0.033 | -0.003 | |
| Price To Book Ratio | 1.838 | 1.030 | -5.402 | -14.737 | 1.664 | |
| Price To Sales Ratio | 11.245 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -5.559 | -5.485 | -2.916 | -2.104 | -1.511 | |
| Price To Operating Cash Flow Ratio | -5.639 | -5.504 | -2.916 | -2.105 | -1.521 | |
| Debt To Assets Ratio | 0.000 | 0.018 | 0.498 | 0.411 | 0.084 | |
| Debt To Equity Ratio | 0.000 | 0.022 | -0.259 | -0.918 | 0.119 | |
| Debt To Capital Ratio | 0.000 | 0.022 | -0.349 | -11.144 | 0.106 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.275 | 1.224 | -0.520 | -2.235 | 1.426 | |
| Working Capital Turnover Ratio | 0.175 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.232 | -2.315 | -3.325 | -2.278 | -5.480 | |
| Operating Cash Flow Sales Ratio | -1.994 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | 1.003 | 1.000 | 1.001 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | -13.096 | -10.574 | -8.561 | -11.800 | |
| Interest Coverage Ratio | 0.000 | -63.844 | -142.040 | -77.890 | -21.904 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -8.509 | -7.153 | -7.629 | -9.183 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -8.509 | -7.153 | -7.629 | -9.183 | |
| Capital Expenditure Coverage Ratio | -69.442 | -290.463 | -1,745,758.829 | -1,895.335 | -155.174 | |
| Dividend Paid And Capex Coverage Ratio | -69.442 | -290.463 | -1,745,758.829 | -1,895.335 | -155.174 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.154 | 0.344 | -1.849 | -1.568 | -0.253 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 81.3% | ▲81.3% | ▲65.0% |
| Ebit Margin | -221.7% | ▼-221.7% | ▼-177.4% |
| Ebitda Margin | -221.7% | ▼-221.7% | ▼-177.4% |
| Operating Profit Margin | -221.7% | ▼-221.7% | ▼-177.4% |
| Pretax Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Continuous Operations Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Net Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Bottom Line Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Current Ratio | 8.654 | ▼-6.343 | ▲2.312 |
| Quick Ratio | 8.093 | ▼-6.721 | ▲1.900 |
| Solvency Ratio | -1.198 | ▲0.371 | ▲1.311 |
| Cash Ratio | 7.240 | ▼-7.248 | ▲1.424 |
| Price To Earnings Ratio | -5.556 | ▼-2.640 | ▼-3.021 |
| Price To Earnings Growth Ratio | 0.132 | ▲0.070 | ▲0.077 |
| Forward Price To Earnings Growth Ratio | 0.132 | ▲0.070 | ▲0.077 |
| Price To Earnings Diluted Ratio | -5.556 | ▼-2.640 | ▼-3.021 |
| Price To Earnings Diluted Growth Ratio | 0.132 | ▲0.070 | ▲0.077 |
| Price To Book Ratio | 1.838 | ▲0.808 | ▲4.959 |
| Price To Sales Ratio | 11.245 | ▲11.245 | ▲8.996 |
| Price To Free Cash Flow Ratio | -5.559 | ▼-0.073 | ▼-2.044 |
| Price To Operating Cash Flow Ratio | -5.639 | ▼-0.135 | ▼-2.102 |
| Debt To Assets Ratio | 0.000 | ▼-0.018 | ▼-0.202 |
| Debt To Equity Ratio | 0.000 | ▼-0.022 | ▲0.207 |
| Debt To Capital Ratio | 0.000 | ▼-0.021 | ▲2.273 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.275 | ▲0.051 | ▲1.041 |
| Working Capital Turnover Ratio | 0.175 | ▲0.175 | ▲0.140 |
| Operating Cash Flow Ratio | -2.232 | ▲0.082 | ▲0.894 |
| Operating Cash Flow Sales Ratio | -1.994 | ▼-1.994 | ▼-1.595 |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | ▲0.011 | ▲0.009 |
| Debt Service Coverage Ratio | 0.000 | ▲13.096 | ▲8.806 |
| Interest Coverage Ratio | 0.000 | ▲63.843 | ▲61.136 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲8.509 | ▲6.495 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲8.509 | ▲6.495 |
| Capital Expenditure Coverage Ratio | -69.442 | ▲221.021 | ▲349564.407 |
| Dividend Paid And Capex Coverage Ratio | -69.442 | ▲221.021 | ▲349564.407 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.154 | ▼-2.498 | ▼-1.058 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $114.9M | $42.7M | $25.5M | $26.1M | $19.1M | |
| Enterprise value | $48.8M | -$4.9M | $25.2M | $25.0M | $6.1M | |
| EV / Sales | 4.78x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -2.40x | 0.64x | -2.88x | -2.01x | -0.49x | |
| EV / Free cash flow | -2.36x | 0.64x | -2.88x | -2.01x | -0.48x | |
| EV / EBITDA | -2.15x | 0.34x | -1.85x | -1.57x | -0.25x | |
| Net debt / EBITDA | 2.92x | 3.31x | 0.02x | 0.07x | 0.54x | |
| Current ratio | 8.65x | 15.00x | 0.73x | 0.57x | 6.75x | |
| Income quality | 0.99x | 0.53x | 0.63x | 0.76x | 0.51x | |
| Graham net-net | $3 | $5 | -$2 | -$1 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 91.2% | 101.3% | 100.5% | 101.4% | 102.8% | |
| Working capital | $69.9M | $46.9M | -$706K | -$2.3M | $13.2M | |
| Invested capital | $70.6M | $47.3M | -$173K | -$1.5M | $14.1M | |
| Return on assets | -25.9% | -28.8% | -561.6% | -410.5% | -151.7% | |
| Operating ROA | -34.7% | -44.6% | -299.8% | -177.5% | -108.5% | |
| Return on tangible assets | -26.1% | -29.1% | -717.3% | -518.5% | -160.4% | |
| Return on equity | -33.1% | -35.3% | 292.2% | 917.7% | -216.5% | |
| Return on invested capital | -32.1% | -24.6% | -918.0% | -12755.3% | -95.2% | |
| Return on capital employed | -32.1% | -25.0% | 5568.1% | 1217.6% | -104.4% | |
| Earnings yield | -18.0% | -34.3% | -54.1% | -62.3% | -130.1% | |
| Free cash flow yield | -18.0% | -18.2% | -34.3% | -47.5% | -66.2% | |
| Capex / Op. cash flow | -1.4% | -0.3% | -0.0% | -0.1% | -0.6% | |
| Capex / Depreciation | 501.1% | 32.9% | 0.0% | 5.4% | 70.8% | |
| Capex / Sales | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 284.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 18.3% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 48.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.5% | 0.8% | 21.7% | 20.8% | 5.4% | |
| Days sales outstanding | 151d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 585d | 0d | 0d | 0d | 0d | |
| Operating cycle | 1128d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 543d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-17 Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26 Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition''s 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation.
- 2026-08-14 Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
- 2026-08-13 Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
- 2026-08-13 Alpha Cognition Q2 Earnings Call Highlights Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer''s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities.
- 2026-08-13 Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter,” said Michael McFadden, Chief Executive Officer of Alpha.
- 2026-08-06 Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-08-03 Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial.
- 2026-07-29 Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer''s Disease VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer''s disease. The patent includes.
- 2026-07-28 Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains? Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn''t suggest further strength down the road.
- 2026-07-23 Playing The Biotech Breakout With Insiders Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL''s Phase 2 efficacy readout for ABCL635 in Q3 and ACOG''s Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.